Launched in March 2020 out of a partnership between LifeMax and Amgen, AmMax Bio, Inc. (“AmMax”) is a privately held, clinical stage biotech company focused on unlocking the therapeutic potential of the CSF1R platform (“colony stimulating factor 1 receptor”) to address diseases with significant unmet medical needs and sizable market potential. We have two clinical stage programs, AMB-051 and AMB-053. Both are ready to enter Phase 2 studies.
AmMax has established a robust pipeline targeting CSF1R. In addition to tenosynovial giant cell tumor wherein an overexpression of CSF1 drives the pathogenesis, AmMax’s pipeline addresses a number of other diseases with critical unmet medical needs, such as idiopathic pulmonary fibrosis and polycystic kidney diseases, by leveraging the dual action of AMB-05X on inflammation and fibrosis.